
Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.

Your AI-Trained Oncology Knowledge Connection!


Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.

Expert perspectives on the utilization of genomic profiling in patients with metastatic castration-sensitive prostate cancer to impact treatment decisions.

A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.

Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.

Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.

Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.

Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.

Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.

A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.

Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.

Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.

After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.

A prostate cancer expert discusses promising and emerging treatments for prostate cancer.

Prostate cancer experts share exciting changes to the prostate cancer treatment landscape and how we are now better equipped to take care of patients with prostate cancer.

A prostate cancer expert reemphasizes importance of open communication between patients and healthcare providers.

Dr. Bobby Liaw discusses importance of setting expectations regarding common side effects and challenges patients might experiences with treatment.

Dr Liaw discusses ways to measure response to treatment and what recent data regarding PSA kinetics has shown.

Dr Bobby Liaw talks about relationship between treatment duration, dosing and efficacy.

Dr. Liaw shares the role disease burden and other factors play in treatment selection.

Published: August 11th 2022 | Updated:

Published: August 24th 2022 | Updated:

Published: September 14th 2022 | Updated:

Published: September 8th 2022 | Updated:

Published: August 24th 2022 | Updated:

Published: September 8th 2022 | Updated: